The sNDA is based on the results of the MELATORCH study in patients with unresectable or metastatic melanoma. Credit: Gorodenkoff/Shutterstock.

The China National Medical Products Administration (NMPA) has accepted for review Junshi Biosciences’ supplemental new drug application (sNDA) for toripalimab (TUOYI) to treat unresectable or metastatic melanoma.

This sNDA is underpinned by the results of the MELATORCH study, a Phase III clinical trial demonstrating positive outcomes for toripalimab in comparison to dacarbazine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The multicentre, randomised, open-label, positive-controlled study assessed the efficacy and safety of toripalimab plus dacarbazine as a first-line treatment for unresectable or metastatic melanoma in systemic treatment-naïve patients.

It was carried out at 11 clinical centres across China.

In September 2023, the trial met its primary endpoint of progression-free survival (PFS).

Patients treated with toripalimab experienced a significant prolongation of PFS compared to those receiving dacarbazine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety profile of toripalimab was consistent with previous studies, with no new safety concerns identified.

Toripalimab is an anti-PD-1 monoclonal antibody designed to hinder the interactions of PD-1 with its ligands PD-L1 and PD-L2, enhancing the immune system’s capability to eliminate tumour cells.

Junshi Biosciences general manager and CEO Dr Jianjun ZOU stated: “In 2018, toripalimab made history as the first domestically developed anti-PD-1 monoclonal antibody approved for second-line and beyond treatment of advanced melanoma, leaving its brilliant mark in China’s pharmaceutical and biotech development.

“Today, our efforts continue with the NMPA’s acceptance of the 12th sNDA for toripalimab, and toripalimab is poised to become China’s first immunotherapy for melanoma. We will work closely with regulatory authorities to provide better clinical treatments to patients as soon as possible.”

In June 2024, the NMPA approved Junshi Biosciences’ toripalimab injection, combined with paclitaxel injection (albumin-bound), for the first-line treatment of recurrent or metastatic triple-negative breast cancer.